Clinical Hold For VaxGen's Anthrax Vaccine Could Lead To Termination Of HHS Contract
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA puts Phase II trial for investigational anthrax vaccine on hold due to stability concerns.
You may also be interested in...
Anthrax Vaccine Gains Homeland Security Liability Protections
BioPort/Emergent’s BioThrax is first vaccine granted DHS protections under 2002 Homeland Security Act.
VaxGen Anthrax Vaccine Delayed
VaxGen expects to supply its recombinant protective antigen anthrax vaccine to the U.S. government beginning in the fourth quarter of 2006, the firm announced Nov. 1
Anthrax Vaccine Is HHS' First Contract Award Under Project BioShield
VaxGen receives $877.5 mil. contract to supply 75 mil. doses of its recombinant protective antigen anthrax vaccine to the national stockpile within three years. The contract is contingent upon FDA clearing the vaccine for use under emergency conditions.